Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation

Introduction: Fast tacrolimus–metabolizing kidney transplant recipients (KTRs) (i.e., tacrolimus trough-level/total daily dose [C0/D < 1.05]) have poorer allograft function; however, their identification in a real-life setting is challenging. We investigated the reproducibility of tacrolimus meta...

Full description

Saved in:
Bibliographic Details
Main Authors: Christophe Masset, Marine Lorent, Clarisse Kerleau, Claire Garandeau, Aurélie Houzet, Simon Ville, Diego Cantarovich, Gilles Blancho, Magali Giral, Jacques Dantal, Julien Branchereau, Agnès Chapelet, Florent Delbos, Clément Deltombe, Lucile Figueres, Charles Ronsin, Thibault Letellier, Clémence Petit, Caroline Gourraud-Vercel, Laurent Nicolet, Christine Kandel-Aznar, Ismaël Chelghaf, Aurélie Meurette, Karine Renaudin, Alexandre Walencik
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024925001032
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849329725687726080
author Christophe Masset
Marine Lorent
Clarisse Kerleau
Claire Garandeau
Aurélie Houzet
Simon Ville
Diego Cantarovich
Gilles Blancho
Magali Giral
Jacques Dantal
Gilles Blancho
Julien Branchereau
Diego Cantarovich
Agnès Chapelet
Jacques Dantal
Florent Delbos
Clément Deltombe
Lucile Figueres
Charles Ronsin
Thibault Letellier
Clémence Petit
Claire Garandeau
Magali Giral
Caroline Gourraud-Vercel
Laurent Nicolet
Christine Kandel-Aznar
Ismaël Chelghaf
Clarisse Kerleau
Christophe Masset
Aurélie Meurette
Karine Renaudin
Simon Ville
Alexandre Walencik
author_facet Christophe Masset
Marine Lorent
Clarisse Kerleau
Claire Garandeau
Aurélie Houzet
Simon Ville
Diego Cantarovich
Gilles Blancho
Magali Giral
Jacques Dantal
Gilles Blancho
Julien Branchereau
Diego Cantarovich
Agnès Chapelet
Jacques Dantal
Florent Delbos
Clément Deltombe
Lucile Figueres
Charles Ronsin
Thibault Letellier
Clémence Petit
Claire Garandeau
Magali Giral
Caroline Gourraud-Vercel
Laurent Nicolet
Christine Kandel-Aznar
Ismaël Chelghaf
Clarisse Kerleau
Christophe Masset
Aurélie Meurette
Karine Renaudin
Simon Ville
Alexandre Walencik
author_sort Christophe Masset
collection DOAJ
description Introduction: Fast tacrolimus–metabolizing kidney transplant recipients (KTRs) (i.e., tacrolimus trough-level/total daily dose [C0/D < 1.05]) have poorer allograft function; however, their identification in a real-life setting is challenging. We investigated the reproducibility of tacrolimus metabolic status during the first months after transplantation and its association with long-term allograft outcomes. Methods: All KTRs between 2000 and 2019 with a functional allograft at 1 month and receiving tacrolimus in our center were included. Fast or slow tacrolimus metabolizers were classified according to the time spent with a C0/D < 1.05 (> 75% = High, < 25% = Low) at various time points posttransplantation. We first determined the earliest accurate time for patient categorization by investigating C0/D variability during the first months. Second, a multivariate cause-specific Cox model studying allograft outcomes was performed in groups identified by their status determined from the earliest accurate timepoint after transplantation. Results: Among 1979 patients included in the analysis, 2 months was the earliest accurate timepoint to determine High patients (85% of High patients identified at 2 months remained High long-term, Brier score = 0.06). Multivariate analysis revealed that High patients determined at 2 months (n = 499) had a significantly higher risk of allograft loss (cause-specific hazard ratio [CS-HR] = 2.00, 95% confidence interval [CI] = 1.48–2.69) and allograft rejection (CS-HR = 1.71, 95% CI = 1.15–2.54) than Low patients after adjustment for confounding factors. Moreover, allograft function was lower in High patients (46.7 vs. 52.9 ml/min, at 3 years, P < 0.0001) with a higher proportion of chronic vascular lesions at 1 year. Conclusion: C0/D is a simple and pragmatic tool capable of identifying patients at risk of rejection and allograft failure as early as the second month posttransplantation.
format Article
id doaj-art-d7ad8b6aff5146ac8c660156683dc1d9
institution Kabale University
issn 2468-0249
language English
publishDate 2025-05-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-d7ad8b6aff5146ac8c660156683dc1d92025-08-20T03:47:10ZengElsevierKidney International Reports2468-02492025-05-011051428144010.1016/j.ekir.2025.02.014Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney TransplantationChristophe Masset0Marine Lorent1Clarisse Kerleau2Claire Garandeau3Aurélie Houzet4Simon Ville5Diego Cantarovich6Gilles Blancho7Magali Giral8Jacques Dantal9Gilles BlanchoJulien BranchereauDiego CantarovichAgnès ChapeletJacques DantalFlorent DelbosClément DeltombeLucile FigueresCharles RonsinThibault LetellierClémence PetitClaire GarandeauMagali GiralCaroline Gourraud-VercelLaurent NicoletChristine Kandel-AznarIsmaël ChelghafClarisse KerleauChristophe MassetAurélie MeuretteKarine RenaudinSimon VilleAlexandre WalencikService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, INSERM, Institute of Transplantation Urology and Nephrology, CHU Nantes, Nantes, France; Correspondence: Christophe Masset, Center for Research in Transplantation and Translational Immunology, 30 boulevard Jean-Monnet, Nantes Cedex, France.Service de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, INSERM, Institute of Transplantation Urology and Nephrology, CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, INSERM, Institute of Transplantation Urology and Nephrology, CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, INSERM, Institute of Transplantation Urology and Nephrology, CHU Nantes, Nantes, FranceService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, INSERM, Institute of Transplantation Urology and Nephrology, CHU Nantes, Nantes, FranceIntroduction: Fast tacrolimus–metabolizing kidney transplant recipients (KTRs) (i.e., tacrolimus trough-level/total daily dose [C0/D < 1.05]) have poorer allograft function; however, their identification in a real-life setting is challenging. We investigated the reproducibility of tacrolimus metabolic status during the first months after transplantation and its association with long-term allograft outcomes. Methods: All KTRs between 2000 and 2019 with a functional allograft at 1 month and receiving tacrolimus in our center were included. Fast or slow tacrolimus metabolizers were classified according to the time spent with a C0/D < 1.05 (> 75% = High, < 25% = Low) at various time points posttransplantation. We first determined the earliest accurate time for patient categorization by investigating C0/D variability during the first months. Second, a multivariate cause-specific Cox model studying allograft outcomes was performed in groups identified by their status determined from the earliest accurate timepoint after transplantation. Results: Among 1979 patients included in the analysis, 2 months was the earliest accurate timepoint to determine High patients (85% of High patients identified at 2 months remained High long-term, Brier score = 0.06). Multivariate analysis revealed that High patients determined at 2 months (n = 499) had a significantly higher risk of allograft loss (cause-specific hazard ratio [CS-HR] = 2.00, 95% confidence interval [CI] = 1.48–2.69) and allograft rejection (CS-HR = 1.71, 95% CI = 1.15–2.54) than Low patients after adjustment for confounding factors. Moreover, allograft function was lower in High patients (46.7 vs. 52.9 ml/min, at 3 years, P < 0.0001) with a higher proportion of chronic vascular lesions at 1 year. Conclusion: C0/D is a simple and pragmatic tool capable of identifying patients at risk of rejection and allograft failure as early as the second month posttransplantation.http://www.sciencedirect.com/science/article/pii/S2468024925001032allograft survivalkidney transplantationtacrolimus toxicity
spellingShingle Christophe Masset
Marine Lorent
Clarisse Kerleau
Claire Garandeau
Aurélie Houzet
Simon Ville
Diego Cantarovich
Gilles Blancho
Magali Giral
Jacques Dantal
Gilles Blancho
Julien Branchereau
Diego Cantarovich
Agnès Chapelet
Jacques Dantal
Florent Delbos
Clément Deltombe
Lucile Figueres
Charles Ronsin
Thibault Letellier
Clémence Petit
Claire Garandeau
Magali Giral
Caroline Gourraud-Vercel
Laurent Nicolet
Christine Kandel-Aznar
Ismaël Chelghaf
Clarisse Kerleau
Christophe Masset
Aurélie Meurette
Karine Renaudin
Simon Ville
Alexandre Walencik
Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
Kidney International Reports
allograft survival
kidney transplantation
tacrolimus toxicity
title Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
title_full Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
title_fullStr Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
title_full_unstemmed Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
title_short Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation
title_sort early determination of tacrolimus concentration dose ratio identifies risk of allograft loss in kidney transplantation
topic allograft survival
kidney transplantation
tacrolimus toxicity
url http://www.sciencedirect.com/science/article/pii/S2468024925001032
work_keys_str_mv AT christophemasset earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT marinelorent earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clarissekerleau earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clairegarandeau earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT aureliehouzet earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT simonville earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT diegocantarovich earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT gillesblancho earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT magaligiral earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT jacquesdantal earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT gillesblancho earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT julienbranchereau earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT diegocantarovich earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT agneschapelet earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT jacquesdantal earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT florentdelbos earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clementdeltombe earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT lucilefigueres earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT charlesronsin earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT thibaultletellier earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clemencepetit earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clairegarandeau earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT magaligiral earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT carolinegourraudvercel earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT laurentnicolet earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT christinekandelaznar earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT ismaelchelghaf earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT clarissekerleau earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT christophemasset earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT aureliemeurette earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT karinerenaudin earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT simonville earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation
AT alexandrewalencik earlydeterminationoftacrolimusconcentrationdoseratioidentifiesriskofallograftlossinkidneytransplantation